Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
Question
Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
Direct answer
Earnings beat of 16 cents against lowered expectations stabilizes XRAY's forward multiple while flat full-year guidance caps intermediate upside. — bullish pressure on XRAY via earnings beat driven by healthcare segment margin preservation against soft dental sales.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-reaffirms-fy26-sales-outlook-e45947
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XRAY | ▲Bull | 1–5 days | earnings beat driven by healthcare segment margin preservation against soft dental sales | 50 |
Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
Earnings beat of 16 cents against lowered expectations stabilizes XRAY's forward multiple while flat full-year guidance caps intermediate upside. — bullish pressure on XRAY via earnings beat driven by healthcare segment margin preservation against soft dental sales.
XRAY exceeded Q2 adjusted EPS estimates with 52 cents vs 36 cents consensus and reiterated FY26 guidance.
- SourceXRAY exceeded Q2 adjusted EPS estimates with 52 cents vs 36 cents consensus and reiterated FY26 guidance.
- TransmissionEarnings beat of 16 cents against lowered expectations stabilizes XRAY's forward multiple while flat full-year guidance caps intermediate upside.
- SummaryDentsply Sirona reported Q2 adjusted EPS of $0.52, exceeding the $0.36 analyst consensus. Revenues declined 4.1% year-over-year, though Wellspect Healthcare expanded by 7.1%. Full-year 2026 revenue guidance was maintained at $3.5B to $3.6B with adjusted EPS at $1.40 to $1.50.
- XRAYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- XRAY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XRAY price vs. pre-event level
- XRAY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XRAY | Bullishdisagreed | 10.72 2026-09-09 | -2.05% | -5.41% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · zacks · 2026-09-08
Related catalysts
- 2026-09-09Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 TargetsXRAY-5.41%
- 2026-09-09Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue ContractionXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 OutlookALGN XRAY-5.41%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.